Educational guide

Atomwise, Hansoh Pharma Enter Into Up-to-$1.5B AI-Based Drug Discovery Partnership

Atomwise and Jiangsu Hansoh Pharmaceutical Group—the Chinese company behind this year’s largest biopharma initial public offering (IPO)—said today they have launched an up-to-$1.5 billion collaboration to design and discover potential drug candidates for up to

Written by Peptide Therapy Guide Editorial TeamPublished September 9, 2026

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The collaboration is intended to combine Atomwise’s AI technology, medicinal chemistry, and protein structure expertise with Hansoh Pharma’s fully integrated R&D, manufacturing, and commercial capabilities, with the aim of accelerating and improving drug discovery and clinical development, Atomwise said.

Atomwise uses AI for its structure-based, drug design technology, which is based on convolutional neural networks along the lines of those that recognize faces in a crowd or enable self-driving cars. Atomwise’s AI technology is designed to enable scientists to predict how well a small molecule will bind to a target protein of interest, as well as remove sole reliance on empirical screening. The company says its AtomNet platform is designed to screen billions of compounds, and has demonstrated success using homology-modeled proteins.

“We have been very impressed by Atomwise’s AI platform, capabilities, and team, and by working together we believe there are exceptional opportunities to develop first-in-class and best-in-class therapies,” Hansoh Pharma president Aifeng Lyu, PhD, said in a statement. “Atomwise is the right partner for Hansoh Pharma to innovate using AI technology and generate a diverse pipeline of small molecules for oncology and other therapeutic areas.”

Oncology is one of six therapeutic areas of focus for Hansoh Pharma; the other five are CNS, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Founded in 1995, Hansoh Pharma is based in Jiangsu with two R&D centers in Lianyungang and Shanghai, and an R&D staff of more than 1,200 employees.

On June 14, Hansoh launched the year’s largest biopharma IPO to date when it sold 551.28 million shares at HK$14.26 ($1.82). The IPO generated HK$7.86 billion (approximately $1 billion) in net proceeds, topping GEN’s A-List of the Top 10 Biopharma IPOs of January-June 2019.

Hansoh Pharma has committed to launching nearly 30 drug candidates by 2020, according to its website, of which 15 would have what the company considers “high growth potential.” The 15 include four “Category 1.1” innovative drugs with new molecular entities, and eight potential first-to-market generic drugs.

“Enormous potential”

“Hansoh Pharma is committed to innovation and shares our mission for global impact on patient health,” Atomwise CEO Abraham Heifets, PhD, stated. “There is exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery.”

Hansoh agreed to pay Atomwise an undisclosed sum toward technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Atomwise estimated that the total value of the partnership could reach $1.5 billion, a projection the company said was based on historical average revenues for small molecule drugs.

Hansoh Pharma is Atomwise’s first collaboration partner based in Asia, but not its first biopharma partner. In June, Atomwise agreed to apply its technology toward developing up to 10 drug targets selected by Eli Lilly through an up-to-$560 million partnership.

Atomwise could generate more than $2.4 billion in royalties through a strategic alliance with Charles River Laboratories signed in January. Charles River has agreed to use Atomwise’s technology in preclinical research, in return for paying Atomwise a technology access fee for each project; payments tied to milestones in hit discovery, hit-to-lead, and lead optimization; plus royalties from clients.

In September 2018, Pfizer agreed to use Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer, in return for paying Atomwise a technology access fee and additional milestone payments for each target protein of interest; the amounts were not disclosed. AbbVie and Merck & Co. have also signed collaboration deals with Atomwise.

Atomwise said it now supports discovery projects in more than 100 universities and hospitals in 19 countries.

Established in 2012, Atomwise has raised over $50 million from venture capital firms to support the development and application of its AI technology. Most of that consists of a $45 million Series A financing completed in March 2018, led by Monsanto Growth Ventures, DCVC (Data Collective), and B Capital Group.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗

02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Related questions

Peptide Therapy Guide Editorial Team

Potential Leukemia Drug Target Found in Epigenetic Protein

Protein Interactions May Now Be Defined in a Quick and Efficient Manner

Mosquitoes Sense Bed Net Insecticides through Their Legs

Cancer Drug Discovery’s “RASzle-Dazzle”